Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

Part of paid clinical trials in New Brunswick, New Jersey.

Sponsor
Rutgers, The State University of New Jersey
Study ID
NCT07643012
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) — RADIATION
    Participants receive moderately hypofractionated MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) delivered via MR-linac to a total dose of 42 Gy in 15 fractions with daily onboard MRI guidance and online adaptive replanning as needed to optimize target coverage and minimize radiation exposure to surrounding organs at risk.

Study Details

To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Jun 30, 2029
Completion
Jun 30, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: MR-guided Adaptive Pelvic IMRT
    Participants receive moderately hypofractionated MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) delivered via MR-linac to a total dose of 42 Gy in 15 fractions with daily onboard MRI and online adaptive replanning as needed to optimize target coverage and minimize radiation exposure to surrounding organs at risk. Vaginal brachytherapy may be administered following IMRT at the treating physician's discretion per institutional standards.

Primary Outcome Measure

Incidence of Acute Grade ≥2 Gastrointestinal and Genitourinary Toxicity [ Time Frame: Within 90 days after completion of treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Rutgers Cancer Institut JerseyNew BrunswickNew Jersey08901
Lara Hathout

Find similar trials in New Brunswick, NJ

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Rutgers Cancer Institut Jersey· New Brunswick, NJ

Related Studies